# Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

> **NCT00409617** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 945 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00409617
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 945 (ACTUAL)
- **Last updated:** 2011-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409617, "Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00409617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*